Page 425 - Read Online

Droste et al. J Cancer Metastasis Treat 2023;9:2 https://dx.doi.org/10.20517/2394-4722.2022.94 Page 21 of 22

106. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT
mutations in breast cancer. Cancer Res 2008;68:6084-91. DOI PubMed PMC
107. Kalinsky K, Hong F, McCourt CK, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH
subprotocol EAY131-Y nonrandomized trial. JAMA Oncol 2021;7:271-8. DOI PubMed PMC
108. Smyth LM, Batist G, Meric-Bernstam F, et al. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-
mutant ER-positive metastatic breast cancer. NPJ Breast Cancer 2021;7:44. DOI PubMed PMC
109. Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase
inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol 2020;21:345-57. DOI
110. Smyth LM, Tamura K, Oliveira M, et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in
patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer. Clin Cancer Res 2020;26:3947-57. DOI PubMed PMC
111. Howell SJ, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase
inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-
free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022;23:851-64. DOI
112. Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 2018;34:427-
438.e6. DOI PubMed PMC
113. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of
breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006;66:8297-308. DOI PubMed
114. Kurian AW, Gong GD, John EM, et al. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups:
findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2009;18:1084-91. DOI
PubMed PMC
115. Antoniou AC, Kuchenbaecker KB, Soucy P, et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated
with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 2012;14:R33. DOI
116. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation
carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev
2012;21:134-47. DOI PubMed PMC
117. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med
2019;381:2416-28. DOI PubMed
118. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J
Med 2018;379:2495-505. DOI
119. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive,
relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3
trial. Lancet Oncol 2017;18:1274-84. DOI
120. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med
2017;377:523-33. DOI
121. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment
of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol
2019;30:558-66. DOI PubMed PMC
122. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med
2018;379:753-63. DOI PubMed
123. Lee KH, Sohn J, Goodwin A, et al. Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a
germline BRCA1/2 mutation enrolled in Asian countries: exploratory subgroup analysis of the phase III EMBRACA trial. Cancer
Res Treat 2021;53:1084-95. DOI PubMed PMC
124. Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in
homologous recombination-related genes. J Clin Oncol 2020;38:4274-82. DOI PubMed
125. Bruno L, Ostinelli A, Waisberg F, et al. Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer
carrying germline pathogenic variants in DNA repair-related genes. JCO Precis Oncol 2022;6:e2100140. DOI PubMed
126. Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 2012;17:191-204. DOI
PubMed PMC
127. Trapani D, Esposito A, Criscitiello C, et al. Entinostat for the treatment of breast cancer. Expert Opin Investig Drugs 2017;26:965-71.
DOI
128. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor
activity against human tumors. Proc Natl Acad Sci USA 1999;96:4592-7. DOI PubMed PMC
129. Connolly RM, Rudek MA, Piekarz R. Entinostat: a promising treatment option for patients with advanced breast cancer. Future
Oncol 2017;13:1137-48. DOI PubMed PMC
130. Shah P, Gau Y, Sabnis G. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells
by reversing the repression of E-cadherin. Breast Cancer Res Treat 2014;143:99-111. DOI PubMed
131. Connolly RM, Zhao F, Miller KD, et al. E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone
receptor-positive advanced breast cancer. a trial of the ECOG-ACRIN cancer research group. J Clin Oncol 2021;39:3171-81. DOI